The NHS in England has become the first health system worldwide to routinely offer belantamab mafodotin (trade name Blenrep), a novel targeted antibody–drug conjugate therapy for multiple myeloma—an incurable blood cancer—approved by NICE on 12 June 2025.
Often referred to as a “Trojan horse” therapy, it delivers a potent cytotoxic payload directly inside cancer cells expressing the BCMA protein, sparing healthy cells .
When used with bortezomib and dexamethasone, it triples progression-free survival—delaying disease advancement for about three years, compared to just over a year with standard daratumumab
Approximately 1,500 patients in England will be eligible annually—those whose cancer has relapsed or failed first-line treatment . Early recipients, such as 60-year-old Paul Silvester, achieved remission within weeks, describing the treatment as life-changing .Prof Peter Johnson (NHS Cancer Director): Thrilled that patients will “get precious time” with loved ones .NICE’s Helen Knight: Emphasized swift access while ensuring cost-effectiveness .Charity advocates: Myeloma UK and Blood Cancer UK say the UK’s approval places the NHS at the leading edge of cancer care .
A “Trojan horse” therapy that sneaks toxic drugs inside cancer cells is being made available on the NHS in England in a world first.
It can halt the blood cancer myeloma for nearly three times longer than current therapies.
Paul Silvester, one of the first people to get it, says the therapy has been “life-changing” and he’s now planning history-themed adventures.
The drug is an advanced form of chemotherapy that hits cancer with a bigger dose, while reducing side-effects.
The Media Times – Unfiltered. Unbiased. Unstoppable.
The Media Times stands as a pillar of fearless journalism, committed to delivering raw, unfiltered, and unbiased news. In a world saturated with noise, we cut through the clutter, bringing facts to the forefront without agenda or compromise.From hard-hitting investigative reports to thought-provoking analysis, we cover politics, healthcare, business, technology, entertainment and global affairs with an unwavering commitment to truth. Our team of dedicated journalists and experts works relentlessly to challenge narratives, expose realities, and hold power accountable.At The Media Times, we don’t just report the news—we shape conversations, spark change, and empower the public with knowledge.
Hindi 
English